Quest Diagnostics Inc.’s DGX robust Advanced Diagnostics offering is poised to drive its growth in the upcoming quarters. Strength in the company’s core business is highly encouraging. Additionally, a ...
On Friday, Quest Diagnostics Inc (DGX) stock saw a modest uptick, ending the day at $160.44 which represents a slight increase of $3.60 or 2.30% from the prior close of $156.84. The stock opened at ...
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
As of November 13, 2024, Quest Diagnostics Incorporated had a $17.9 billion market capitalization, putting it in the 87th percentile of companies in the Health Care Providers & Services industry.
Quest Diagnostics Incorporated has a 1 year low of $123.04 and a 1 year high of $162.59. The firm has a market cap of $17.90 billion, a P/E ratio of 21.58, a price-to-earnings-growth ratio of 2.79 ...